ABAC Therapeutics

company

About

ABAC Therapeutics (ABAC) develops new targeted antibiotics for patients with severe infections.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
€16M
Industries
Biotechnology,Life Science,Therapeutics
Founded date
Jan 1, 2014
Number Of Employee
1 - 10
Operating Status
Active

ABAC Therapeutics is aimed at seeking first-in-class drugs for precision treatment of MDR Gram-negative infections. While potent pathogen-specific antibacterial activity is essential, we believe that it is necessary to incorporate early other pharmaceutical properties, such as suitable pharmacokinetics and toxicological characteristics, to maximize the chance of success in clinical development.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€16M
ABAC Therapeutics has raised a total of €16M in funding over 2 rounds. Their latest funding was raised on Feb 15, 2018 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 15, 2018 Series A €16M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
ABAC Therapeutics is funded by 1 investors. Global health sciences venture fund are the most recent investors.
Investor Name Lead Investor Funding Round
Global health sciences venture fund Series A